Dr. Masey Ross is an associate professor in the Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine at Virginia Commonwealth University (VCU), VCU School of Medicine. Ross is also the medical director of Clinical Research Affiliations and the medical director of the Integrative Health Program at VCU Massey Cancer Center.

Dr. Masey Ross 

Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer. 

How Biomarker Testing Informs Metastatic Breast Cancer Care

Conducting biomarker testing is essential in order to make informed treatment decisions for those with breast cancer, according to Dr. Masey Ross, who added that this is because the testing provides detailed information about the cancer’s characteristics.

Next-generation sequencing can reveal additional targetable markers that may expand therapy options. Patient history and prior therapies also go into making treatment decisions. This is because for those with metastatic breast cancer, balancing effective cancer control with quality of life is critical, as these patients often need long-term treatment.

Managing side effects and maintaining well-being help patients stay active and focused on their daily lives while undergoing therapy, supporting a personalized approach tailored to each individual’s situation, Ross explained in an interview with CURE.

She is an associate professor in the Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine at Virginia Commonwealth University (VCU), VCU School of Medicine. Ross is also the medical director of Clinical Research Affiliations and the medical director of the Integrative Health Program at VCU Massey Cancer Center.

What specific aspects of biomarker testing are important for patients with breast cancer to know, and what questions or concerns should the patient be asking their care team?

I think it’s important to consider, each time we’re picking a new therapy, that as oncologists, we’re considering a lot of different factors. These include the patient’s history and prior experience with therapies. It also [encompasses] having the most up-to-date information about the cancer cells themselves, including the phenotype, like ERPR and HER2. [We also can utilize] next-generation sequencing to look for any targetable biomarkers that may open up additional treatment options.

Quality of life is [also] extremely important when considering treatment for metastatic breast cancer. You have to balance quality, because all of these therapies are things patients have to be on indefinitely. We want to make sure people are feeling well and able to spend their time doing what they want, while also balancing treatment to control their cancer.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education,

don’t forget to subscribe to CURE®’s newsletters here.

Dr. Masey Ross

How Biomarker Testing Can Inform Metastatic Breast Cancer Care

Latest News